Alphamab Oncology

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.

Profit setback for Simcere Pharma in novel drugs quest

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
2096.HK

Recent Articles

RELATED ARTICLES

  1. The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.
    Profit setback for Simcere Pharma in novel drugs quest
    2096.HK
  2. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
  6. HBM gets health boost from drug licensing deals
    2142.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva